| abstract |
REFERRING TO SUBSTITUTE BIPHENYL COMPOUNDS OF FORMULA (I), WHERE G IS N OR CR11a; J ES NO CR11b; L IS NO CR11c; K IS NO CR11d; R11a, R11b, R11c AND R11d ARE EACH H, F, Cl, AMONG OTHERS; A IS ALKYL (C1-C12), ALKENYL (C2-C12), -O-ALKYL (C1-C12), AMONG OTHERS; X IS O O S; W, Y, and Z ARE EACH N O CR13; R13 IS H, F, (C1-C4) ALKYL, AMONG OTHERS; R1 IS H, ALKYL (C1-C6), ALKENYL (C2-C6), AMONG OTHERS; R1a IS H O ALKYL (C1-C4); R2 IS H, F, CF3, AMONG OTHERS; R3 IS H, -OH, -O-(C1-C3) ALKYL, -S-(C1-C2) ALKYL; R7 AND R8 ARE EACH H O ALKYL (C1-C4); R9 AND R10 ARE EACH H O ALKYL (C1-C4); R12a, R12b, AND R11c ARE EACH H, F, ALCOXY (C1-C4), AMONG OTHERS; q IS 1 OR 2. PREFERRED COMPOUNDS ARE: ACID (3R) -3- (3 - (((2- (BUTYLOXY) -2'-FLUORO-5 '- (METHYLOXY) -1,1'-BIPHENYL-4- IL) METHYL) OXY) PHENYL) -5-HEXENOIC ACID, (3S) -3- (3 - (((2- (5,5-DIMETHYL-1-CYCLOPENTEN-1-IL) -2'-FLUORO-5 '- (METILOXY) -1,1'-BIPHENYL-4-IL) METHYL) OXY) PHENYL) BUTANOIC, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE GPR40 RECEPTOR MODULATORS AND / OR GLP1 SECRETION STIMULATORS, BEING USEFUL FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, HYPERGLYCEMIA, AMONG OTHERS |